| Related Articles |
Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Cardiol J. 2015 Oct 27;
Authors: Celık T, Balta S, Demır M, Yıldırım AO, Kaya MG, Ozturk C, Demırkol S, Unlu M, Kılıc S, Aydın İ, Iyısoy A
Abstract
BACKGROUND: The red cell distribution width-platelet ratio(RPR), a novel inflammatory marker has currently predicted inflammation in chronic diseases. It may be associated with adverse outcomes among artery disease but its prognostic value in ST-segment elevation myocardial infarction(STEMI) treated with primary percutaneous coronary intervention(pPCI) has not been fully investigated. There is no data regarding the association between RPR and in-hospital major adverse cardiovascular events(MACEs). This study evaluated the relations between pre-procedural RPR and the in-hospital and long-term outcomes in STEMI patients undergoing pPCI.
METHODS: This study included 580 STEMI patients(77% men, mean age=59±12 years). The patients were divided into 2 groups according to thrombolysis in myocardial infarction (TIMI) flow grades after primary PCI. No-reflow was defined as a post-PCI TIMI flow grade of 0, 1 or 2(Group 1). Angiographic success was defined as TIMI flow grade 3 (Group 2).
RESULTS: WBC count, neutrophil and lymphocyte percentages, RDW, platecrit, neutrophil-lymphocyte ratio(NLR) and RPR values were higher among patients with no-reflow. On multivariate analysis, pain to balloon time, multivessel disease, TIMI thrombus grade, tirofiban, aspirin, previous CAD, NLR, platecrit and RPR remained independent predictors of no reflow after primary PCI. Patients in no-reflow group tended to be higher percent in-hospital MACE, including nonfatal MI and cardiovacular mortality compared to those of reflow patients.
CONCLUSIONS: Admission NLR, platecrit and RPR are independent correlates of no-reflow and in-hospital MACEs among patients with STEMI undergoing pPCI.
PMID: 26503078 [PubMed - as supplied by publisher]